Development and validation of a blood biomarker risk prediction model for postmenopausal endometrioid endometrial cancer - Top-Institutions - MDSpire

Development and validation of a blood biomarker risk prediction model for postmenopausal endometrioid endometrial cancer

  • By

  • Hubin Xu

  • Mengyu Zhang

  • Huinan Zhu

  • Haimin Jiang

  • Wenjie Zeng

  • Xiaoyan Chen

  • Huafeng Shou

  • Lingqian Zhao

  • July 3, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Duke University Health System
    Duke University Health System

    Durham, North Carolina

    Key Differentiators

    • Gynecologic Oncology

  • #2

    Zhejiang Provincial People’s Hospital
    Zhejiang Provincial People’s Hospital

    Hangzhou, Zhejiang

    Key Differentiators

    • Gynecologic Oncology

  • #3

    Mount Sinai
    Mount Sinai

    New York, New York

    Key Differentiators

    • Gynecologic Oncology

  • #4

    Columbia
    Columbia

    New York, New York

    Key Differentiators

    • Gynecologic Oncology

  • #5

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Gynecologic Oncology

Original Source(s)

Development and validation of a blood biomarker risk prediction model for postmenopausal endometrioid endometrial cancer

  • by Hubin Xu, Mengyu Zhang, Huinan Zhu, Haimin Jiang, Wenjie Zeng, Xiaoyan Chen, Huafeng Shou, Lingqian Zhao

  • July 3, 2026

Related Content

Transfer RNA expression, modification, and derived small RNAs in cancer biology and clinical potential

Transrectal vs. transvaginal oocyte retrieval in patients requesting egg freezing for fertility preservation: a prospective observational study

A multiscale model reveals how ERK/p38-regulated dormancy shapes tumor-immune dynamics and immunoediting outcomes